BioSpace News Archive

The successful round will accelerate SomaLogic’s goal of becoming the world’s leading provider of precision digital health insights.

Cirius Therapeutics announced today that Dennis Fenton, Ph.D., has been appointed to the company’s board of directors as an independent member.

Pfenex today announced the appointment of Susan A. Knudson as CFO, effective February 1, 2018.

The new hires will join current CEO-in-residence, Shafique Virani, M.D., who is focused on central nervous system and oncology development programs.

Through the collaboration, the companies will combine BLI’s platform - which utilizes a light-based, nano-fluidic method to select, characterize, culture and export single cells - with Pfizer’s expertise in gene editing, sequencing, and molecular biology, as well as B-cell screening, to help advance the research aims and influence the development of the Beacon platform.

ImmunoGen today announced that the first patient has been treated with IMGN632 in a Phase 1 clinical trial of patients with CD123-positive hematological malignancies.

Exelixis today announced an amendment to the protocol for the phase 1b trial of cabozantinib in combination with atezolizumab (TECENTRIQ) in patients with locally advanced or metastatic solid tumors.

The launch and updated claims follow NuVasive’s September 2017 acquisition of Vertera Spine.

Asana BioSciences today announced that ASN002, its oral once daily dual JAK/SYK inhibitor, has achieved clinical efficacy in a proof of concept study in patients with moderate-to-severe atopic dermatitis.

Lycera’s Phase 1b study is expected to enroll a total of approximately 18 patients with metastatic NSCLC.